Rayner
David Forsythe has over 13 years of work experience, primarily in the medical device industry. David joined Stryker in 2004 and held various roles during their tenure. From 2004 to 2006, they served as a QA/RA Director and was responsible for all regulatory and quality assurance issues. In this role, they received media training and was involved in crisis management. David became the Clinical Research Director for the EMEA region in 2007 and led a pan-European clinical research group. Their responsibilities included managing clinical research studies, protocol writing, monitoring, and publishing. In 2011, they were promoted to the role of VP- Quality and Operations Europe and became a member of the European Board. In this capacity, they led a team of approximately 400 people and was responsible for quality and regulatory, supply chain, and logistics functions for Europe. David also contributed to global and pan-European projects. In 2017, David joined Rayner as the COO.
David Forsythe started their education at Edinburgh Napier University in 1992, where they pursued a degree in Chemistry. David studied there for five years, completing their degree in 1997. Following this, David undertook their MBA at The University of Edinburgh from 1997 to 2000. The information provided does not specify a field of study for their MBA.
This person is not in any offices
Rayner
5 followers
Rayner designs and manufactures intraocular lenses and proprietary injection devices for use in cataract surgery. When Sir Harold Ridley designed the world’s first IOL in 1949, he chose Rayner to manufacture this ground-breaking invention.With more than 65 years of continuous growth and experience, we remain at the forefront of innovation. Weare focused on providing the best IOLs for clinicians and patients and are driven by science to improve patient outcomes and safety.Primary IOLs Our FDA-approved C-flex aspheric (aberration-neutral) monofocal IOL, as well as our toric and multifocal IOL families are now complemented by the RayOne fully preloaded monofocal IOL injection system. Supplementary IOLsDesigned to be implanted in the ciliary sulcus, Rayner Sulcoflex Pseudophakic Supplementary IOLs are available as aspheric, toric, multifocal and multifocal lenses, and offer a reversible solution for correcting residual post-operative refractive errors following the implantation of a conventional IOL in the capsular bag.OVDsOur Ophteis range offers a full spectrum of OVDs from dispersive to cohesive, enabling surgeons to select the OVD best suited to each specific cataract procedure. Ophteis FR Pro with sorbitol -- designed to deliver a new level of corneal endothelial protection from phaco induced trauma -- is the flagship product of Rayner’s ‘Ophteis’ OVD suite. PharmaceuticalsAlthough the intraocular lens plays a leading role in the visual outcomes of cataract and refractive surgery, the pharmaceuticals that manage the tear film and inflammation are critical to the end result. For that reason, Rayner recently acquired the business of Moorfields Pharmaceuticals. The acquisition will enable us to offer an even wider range of ophthalmic tools that aid and streamline the surgical process whilst remaining focused on the visual outcome for the patient.Rayner markets its IOL portfolio and related products worldwide through a network of distributors in over 80 countries with direct markets in UK, Germany & Austria, the United States of America, Italy and Spain. We have the world’s longest commercial history of IOL design and manufacturing and have worked with cataract surgeons for longer than anyone else.In 2016, Rayner transferred its global headquarters to a brand new state of the art manufacturing plant, which has dramatically increased the company’s production capacity.